Next Article in Journal
Previous Article in Journal
Pharmaceuticals 2012, 5(12), 1393-1408; doi:10.3390/ph5121393
Article

Biosimilars: Company Strategies to Capture Value from the Biologics Market

1,*  and 2,*
Received: 8 November 2012; in revised form: 5 December 2012 / Accepted: 6 December 2012 / Published: 12 December 2012
View Full-Text   |   Download PDF [640 KB, uploaded 12 December 2012]   |   Browse Figures
Abstract: Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximising the value generated from the biologics patent cliff.
Keywords: biosimilar; patent cliff; biopharmaceutical industry; market strategy; biologics biosimilar; patent cliff; biopharmaceutical industry; market strategy; biologics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Calo-Fernández, B.; Martínez-Hurtado, J.L. Biosimilars: Company Strategies to Capture Value from the Biologics Market. Pharmaceuticals 2012, 5, 1393-1408.

AMA Style

Calo-Fernández B, Martínez-Hurtado JL. Biosimilars: Company Strategies to Capture Value from the Biologics Market. Pharmaceuticals. 2012; 5(12):1393-1408.

Chicago/Turabian Style

Calo-Fernández, Bruno; Martínez-Hurtado, Juan L. 2012. "Biosimilars: Company Strategies to Capture Value from the Biologics Market." Pharmaceuticals 5, no. 12: 1393-1408.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert